Lupin Partners with Sino Universal Pharmaceuticals to Launch Tiotropium DPI for COPD Patients in China

Lupin Limited, one of India’s top global pharmaceutical companies, announced on June 16, 2025, that it has signed a license and supply agreement with China-based Sino Universal Pharmaceuticals to commercialise its Tiotropium Dry Powder Inhaler (DPI), 18 mcg per capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the Chinese market.

This partnership marks an important step in Lupin’s global expansion strategy, particularly in the field of respiratory medicine. It also ensures that COPD patients in China will gain access to high-quality and affordable treatment options.

Terms of the Agreement

According to the agreement:

• Sino Universal Pharmaceuticals (SUP) will handle regulatory approvals and the distribution process for the Chinese market

• Lupin will remain the marketing authorisation holder and will be responsible for manufacturing the inhaler

• Both companies will collaborate to launch and scale access to Tiotropium DPI across China

This ensures a streamlined strategy where both regulatory expertise and manufacturing excellence are leveraged to serve one of the world’s largest pharmaceutical markets.

About Tiotropium DPI

Tiotropium DPI is a widely used long-acting bronchodilator prescribed for patients with COPD, a progressive lung disease that includes conditions such as chronic bronchitis and emphysema. The inhaler works by relaxing the airway muscles, allowing easier breathing, and is proven to:

• Improve lung function

• Enhance quality of life

• Reduce COPD exacerbations and hospitalisations

Given the rising prevalence of respiratory disorders in China due to urbanisation and pollution, the launch of Tiotropium DPI is both timely and essential.

Executive Statements

Fabrice Egros, President of Corporate Development at Lupin, said:

We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for respiratory diseases like COPD and establishing leadership in global respiratory health.

He added that SUP is a trusted partner, and this collaboration is key to enhancing patient access to innovative and affordable healthcare solutions in China.

Wang Li, President of Sino Universal Pharmaceuticals, expressed similar confidence in the deal:

We are honoured to collaborate with Lupin, a global pharmaceutical leader, to bring Tiotropium DPI to the Chinese market. Lupin’s innovation-driven approach perfectly aligns with our mission. This partnership will allow more Chinese patients to benefit from international respiratory healthcare advancements.

Strategic Significance

This deal will not only strengthen Lupin’s global footprint but also reaffirm its commitment to patient-centric healthcare delivery. For Sino Universal, the partnership reflects its ongoing role as a bridge between global innovation and local healthcare access.

With respiratory disorders on the rise in China, and millions requiring long-term treatment, the timely availability of quality therapies like Tiotropium DPI can significantly improve public health outcomes.

About Lupin

Headquartered in Mumbai, Lupin Limited is a leading pharmaceutical company with a presence in over 100 countries, specialising in:

• Branded and generic formulations

• Complex generics and biosimilars

• Active pharmaceutical ingredients

• Diagnostic and digital healthcare solutions

The Current active IPO are Oswal Pumps, Patil Automation, Samay Projects Services, Aten Papers, Monolithisch India.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.